Bristol-Myers Squibb Ce Statistics
Share Statistics
Bristol-Myers Squibb Ce has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is 13.23 and the forward PE ratio is null.
| PE Ratio | 13.23 |
| Forward PE | null |
| PS Ratio | 2.36 |
| Forward PS | null |
| PB Ratio | 3.61 |
| P/FCF Ratio | 8.39 |
| PEG Ratio | n/a |
Enterprise Valuation
Bristol-Myers Squibb Ce has an Enterprise Value (EV) of 136.16B.
| EV / Earnings | 16.97 |
| EV / Sales | 3.03 |
| EV / EBITDA | 7.03 |
| EV / EBIT | 7.9 |
| EV / FCF | 10.76 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 1.35.
| Current Ratio | 1.43 |
| Quick Ratio | 1.31 |
| Debt / Equity | 1.35 |
| Total Debt / Capitalization | 57.47 |
| Cash Flow / Debt | 0.35 |
| Interest Coverage | 14.79 |
Financial Efficiency
Return on equity (ROE) is 0.27% and return on capital (ROIC) is 23.15%.
| Return on Equity (ROE) | 0.27% |
| Return on Assets (ROA) | 0.08% |
| Return on Capital (ROIC) | 23.15% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0.47 |
| Inventory Turnover | 4.02 |
Taxes
| Income Tax | 400.00M |
| Effective Tax Rate | 0.05 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Bristol-Myers Squibb Ce's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 55.56 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Bristol-Myers Squibb Ce had revenue of $45.01B and earned $8.03B in profits. Earnings per share was $3.88.
| Revenue | 45.01B |
| Gross Profit | 34.31B |
| Operating Income | 17.24B |
| Net Income | 8.03B |
| EBITDA | 19.37B |
| EBIT | 17.24B |
| Earnings Per Share (EPS) | 3.88 |
Balance Sheet
The company has $11.46B in cash and $41.46B in debt, giving a net cash position of -$30.00B.
| Cash & Cash Equivalents | 11.46B |
| Total Debt | 41.46B |
| Net Cash | -30.00B |
| Retained Earnings | 28.77B |
| Total Assets | 93.67B |
| Working Capital | 5.44B |
Cash Flow
In the last 12 months, operating cash flow was $13.86B and capital expenditures -$1.21B, giving a free cash flow of $12.65B.
| Operating Cash Flow | 13.86B |
| Capital Expenditures | -1.21B |
| Free Cash Flow | 12.65B |
| FCF Per Share | 6.11 |
Margins
Gross margin is 76.24%, with operating and profit margins of 38.31% and 17.83%.
| Gross Margin | 76.24% |
| Operating Margin | 38.31% |
| Pretax Margin | 18.75% |
| Profit Margin | 17.83% |
| EBITDA Margin | 43.03% |
| EBIT Margin | 38.31% |
| FCF Margin | 28.11% |
Dividends & Yields
CELG-RI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for CELG-RI.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 6 |